Aduhelm Label Update Includes Seizure Risk And Recommends More MRIs
Executive Summary
FDA updated the prescribing information for Biogen’s Alzheimer's therapy after four cases of seizures were reported.
You may also be interested in...
Medicare Alzheimer’s Decision Varies Evidence Mandate For Accelerated vs. Traditional Approvals
Final Medicare national coverage determination aims to set up a ‘nimble’ system to allow for broad and rapid patient access to drugs for Alzheimer’s disease following traditional approval while retaining a more restrictive approach for accelerated approvals.
Aduhelm Adverse Event Reports Come In, Another Potential Hurdle To Uptake
One patient treated with Aduhelm died who was diagnosed with cerebral edema thought to be ARIA-E, a known risk, Biogen confirmed.
Biogen Says Physician Debate About Aduhelm More ‘Pervasive’ Than Anticipated
CEO Michel Vounatsos and US president Alisha Alaimo outlined plans to overcome the Alzheimer’s drug’s launch challenges and hinted at lower sales expectations at a Morgan Stanley investor event.